Redmile Group’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-5,296,643
| Closed | -$83.3M | – | 77 |
|
|
2024
Q1 | $83.3M | Buy |
5,296,643
+495,103
| +10% | +$7.62M | 3.06% | 7 |
|
|
2023
Q4 | $77.4M | Buy |
4,801,540
+326,156
| +7% | +$4.16M | 2.77% | 7 |
|
|
2023
Q3 | $56.9M | Sell |
4,475,384
-403,182
| -8% | -$5.56M | 2.71% | 8 |
|
|
2023
Q2 | $68.7M | Sell |
4,878,566
-703,539
| -13% | -$10.1M | 2.64% | 7 |
|
|
2023
Q1 | $86.2M | Buy |
5,582,105
+1,988,788
| +55% | +$33.2M | 3.74% | 4 |
|
|
2022
Q4 | $58.9M | Buy |
3,593,317
+620,288
| +21% | +$10.1M | 2.41% | 13 |
|
|
2022
Q3 | $55M | Buy |
2,973,029
+1,542,112
| +108% | +$24.2M | 2.13% | 15 |
|
|
2022
Q2 | $18.8M | Buy |
1,430,917
+766,100
| +115% | +$8.46M | 0.72% | 37 |
|
|
2022
Q1 | $6.16M | Hold |
664,817
| – | – | 0.19% | 58 |
|
|
2021
Q4 | $6.5M | Sell |
664,817
-3,366,704
| -84% | -$63.3M | 0.15% | 62 |
|
|
2021
Q3 | $137M | Sell |
4,031,521
-213,200
| -5% | -$6.8M | 2.39% | 14 |
|
|
2021
Q2 | $155M | Sell |
4,244,721
-106,923
| -2% | -$4.14M | 2.3% | 11 |
|
|
2021
Q1 | $195M | Sell |
4,351,644
-86,324
| -2% | -$4.02M | 2.75% | 7 |
|
|
2020
Q4 | $253M | Sell |
4,437,968
-336,950
| -7% | -$20M | 3.07% | 8 |
|
|
2020
Q3 | $245M | Sell |
4,774,918
-204,023
| -4% | -$9.99M | 4.5% | 6 |
|
|
2020
Q2 | $297M | Sell |
4,978,941
-137,322
| -3% | -$7.35M | 5.49% | 3 |
|
|
2020
Q1 | $211M | Buy |
5,116,263
+406,765
| +9% | +$22.6M | 5.91% | 3 |
|
|
2019
Q4 | $293M | Sell |
4,709,498
-71,400
| -1% | -$3.39M | 7.01% | 1 |
|
|
2019
Q3 | $162M | Buy |
4,780,898
+2,557,522
| +115% | +$75.7M | 5.43% | 4 |
|
|
2019
Q2 | $50.1M | Buy |
2,223,376
+594,723
| +37% | +$13.9M | 1.42% | 24 |
|
|
2019
Q1 | $37.8M | Sell |
1,628,653
-24,527
| -1% | -$642K | 1.11% | 30 |
|
|
2018
Q4 | $34.7M | Buy |
1,653,180
+176,600
| +12% | +$4.34M | 1.4% | 27 |
|
|
2018
Q3 | $57.2M | Sell |
1,476,580
-500
| -0% | -$18.5K | 1.76% | 20 |
|
|
2018
Q2 | $58.1M | Buy |
1,477,080
+655,800
| +80% | +$19.3M | 1.97% | 18 |
|
|
2018
Q1 | $16.5M | Buy |
821,280
+137,400
| +20% | +$3.48M | 0.64% | 44 |
|
|
2017
Q4 | $14.7M | Sell |
683,880
-39,000
| -5% | -$764K | 0.64% | 47 |
|
|
2017
Q3 | $12M | Buy |
+722,880
| New | +$13.2M | 0.59% | 44 |
|
Other funds holding DCPH
Redmile Group's DCPH Position: Q2 2024 in Review
Redmile Group sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 5,296,643 shares — an estimated $83.3M sold.
Redmile Group first reported a position in DCPH in Q3 2017 and held it in 27 quarters. The position peaked at $297M in Q2 2020. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.
- Redmile Group reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Redmile Group sold 5,296,643 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $83.3M.
- Redmile Group first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 27 quarters.
- Redmile Group's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $297M in Q2 2020.
- 1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Redmile Group's 13F filing for Q2 2024, filed 14 Aug 2024.